GSK and CureVac are making 'next-generation' vaccines that they say can tackle multiple COVID-19 variants at onceBusiness Insider • 02/03/21
GSK and CureVac join forces to develop vaccines targeting new COVID-19 variantsMarket Watch • 02/03/21
CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge InfectionAccesswire • 01/11/21
This Covid Vaccine Stock Just Rocketed On A Deal With Pharma Giant BayerInvestors Business Daily • 01/07/21
CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare WorkersAccesswire • 12/21/20